Targeting the NCAPD3 gene activates EGFR and ASNS as two pivotal contributors to gastric cancer progression Effect of NCAPD3 knockdown in gastric cancer
Gastroenterology and Hepatology from Bed to Bench,
Vol. 17 No. 4 (2024),
2 Azar 2024
https://doi.org/10.22037/ghfbb.v17i4.3031
Abstract
Aim: This study was conducted to discover the effect of NCAPD3 knockdown on the gene expression profile of gastric cancer. Background: Gastric cancer, a potentially fatal disease, requires thorough evaluation for targeted interventions. Through the post-analysis of microarray data, it is crucial to further examine the impact of NCAPD3 (Non-SMC condensin II complex subunit D3) inhibition in gastric cancer, emphasizing the need for a more comprehensive analysis of this knockdown.
Methods: Use of Cytoscape and its plug-ins for protein-protein interaction network analysis enables the identification of genes that significantly affect network stability. These hub-bottlenecks are regulated due to the NCAPD3 inhibition and some of them act as compensators in this condition. The hub-bottlenecks pathways identified by ClueGO indicate their relationships in underlying mechanisms of knockdown. These identified central differentially expressed genes could be considered eligible targets for therapeutic interventions. Some of them play compensative roles while others are regulated in NCAPD3 knockdown.
Results: It can be concluded that some of the hub-bottlenecks contribute to compensation mechanisms including NPM1, PTEN, EGFR, HSPA5, and ASNS, while the other ones including HSPA4, DHX9, CAV1, MAP1LC3B, and SRSF1 are among the regulated genes.
Conclusion: In particular, the up-regulation of EGFR and ASNS genes in the knockdown scenario could significantly impact and deteriorate cancer treatment outcomes after comprehensive validation studies.
- Gastric cancer
- Network analysis
- Gene expression
- NCAPD3
How to Cite
References
Burz C, Pop V, Silaghi C, Lupan I, Samasca G. Prognosis and treatment of gastric cancer: a 2024 update. Cancers 2024;16:1708.
Lin L-L, Huang H-C, Juan H-F. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteom 2012;75:3081-97.
Liu W, Yang Q, Liu B, Zhu Z. Serum proteomics for gastric cancer. Clin Chim Acta 2014;431:179-84.
Hosseinpour Z, Azodi MZ, Sherafat SJ, Tavirani MR. Targeting colon cancer via antimicrobial RT2 peptide: a system biology study. Gastroenterol Hepatol Bed Bench 2023;16:415.
Rezaei-Tavirani M, Rezaei-Tavirani S, Mansouri V, Rostami-Nejad M, Rezaei-Tavirani M. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac J Cancer Prev 2017;18:3357.
Nithya C, Kiran M, Nagarajaram HA. Dissection of hubs and bottlenecks in a protein-protein interaction network. Comput Biol Chem 2023;102:107802.
Zhen Y, Guanghui L, Xiefu Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther 2014;21:491-7.
Zhang S-Y, Luo Q, Xiao L-R, Yang F, Zhu J, Chen X-Q, et al. Role and mechanism of NCAPD3 in promoting malignant behaviors in gastric cancer. Front Pharmacol 2024;15:1341039.
Saito R, Smoot ME, Ono K, Ruscheinski J, Wang P-L, Lotia S, et al. A travel guide to Cytoscape plugins. Nat Methods 2012;9:1069-76.
Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: network analysis and visualization of proteomics data. J Proteome Res 2018;18:623-32.
Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013;29:661-3.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.
Cao W, Zeng Z, Lan J, Yang Y, Lu M, Lei S. Knockdown of FUT11 inhibits the progression of gastric cancer via the PI3K/AKT pathway. Heliyon 2023;9:17600.
Zhang Z, Ning M, Li L, Li Z, Wang Y, Zhao J. Knockdown of ASF1B inhibits cell proliferation, migration, invasion and cisplatin resistance in gastric cancer through the Myc pathway. Oncol Lett 2023;25:1-11.
Gao Q, Chen Y, Yue L, Li Z, Wang M. Knockdown of TMEM132A restrains the malignant phenotype of gastric cancer cells via inhibiting Wnt signaling. Nucleosides Nucleotides Nucleic Acids 2023;42:343-57.
Leal MF, Mazzotti TKF, Calcagno DQ, Cirilo PDR, Martinez MC, Demachki S, et al. Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. BMC Gastroenterol 2014;14:1-10.
Chang-An G, Xiao-Lu S, Wen-Jie W, Tian-Hong X, Xiao-Meng C, Shao-Bin Y, et al. NPM1 is a diagnostic and prognostic biomarker associated with the clinicopathological characteristics of gastric cancer. Neoplasma 2022;69.
Liu H-B, Guo C-A, Su X-L, Wang W-J, Xia T-H, Cao X-M, et al. NPM1 is a prognostic biomarker and correlated with clinicopathological characteristics in gastric cancer. Research Square 2022.
Yazdi SAM, Hoseini F, Javadi AE, Nazar E. Evaluation of phosphatase and tensin homologue (PTEN) expression in gastric cancer and its relationship with histopathological findings. Rev Esp Patol 2024;57:3-8.
Fei G, Ebert MP, Mawrin C, Leodolter A, Schmidt N, Dietzmann K, et al. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur J Gastroenterol Hepatol 2002;14:297-303.
Ashrafizadeh M, Najafi M, Ang HL, Moghadam ER, Mahabady MK, Zabolian A, et al. PTEN, a barrier for proliferation and metastasis of gastric cancer cells: from molecular pathways to targeting and regulation. Biomedicines 2020;8:264.
Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, et al. Heat shock protein A4 controls cell migration and gastric ulcer healing. Dig Dis Sci 2015;60:850-7.
Park JM, Kim JW, Hahm KB. HSPA4, the “evil chaperone” of the HSP family, delays gastric ulcer healing. Springer; 2015. p. 824-6.
Yashiro M, Morisaki T, Hasegawa T, Kakehashi A, Kinoshita H, Fukuoka T, et al. Novel biomarkers for gastric cancer stem cells utilizing comparative proteomics analysis. Cancer Res 2015;75:1405-.
Tausif YM, Thekkekkara D, Sai TE, Jahagirdar V, Arjun H, Meheronnisha S, et al. Heat shock protein paradigms in cancer progression: future therapeutic perspectives. 3 Biotech 2024;14:96.
Wang Y, Guo Y, Song Y, Zou W, Zhang J, Yi Q, et al. A pan-cancer analysis of the expression and molecular mechanism of DHX9 in human cancers. Front Pharmacol 2023;14:1153067.
Zhang J, Wang Z, Wang K, Xin D, Wang L, Fan Y, et al. Increased Expression of SRSF1 Predicts Poor Prognosis in Multiple Myeloma. J Oncol 2023;2023:9998927.
Wan L, Lin K-T, Rahman MA, Ishigami Y, Wang Z, Jensen MA, et al. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discov 2023;13:1678-95.
Lo Giudice A, Asmundo MG, Broggi G, Cimino S, Morgia G, Di Trapani E, et al. The clinical role of SRSF1 expression in cancer: a review of the current literature. Appl Sci 2022;12:2268.
Deng C, Gong S, Lin L, Tang J, Pang X, Wu P. A human pan-cancer system analysis of heat shock protein family A member 5. Am J Cancer Res 2023;13:1698.
Yu Q, Wang X, Wang L, Zheng J, Wang J, Wang B. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells. Scand J Gastroenterol 2016;51:1220-6.
Zhao X, He Y, Gao J, Fan L, Li Z, Yang G, et al. Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer. PLoS One 2013;8:59102.
Yu S, Li G, Wang Z, Wang Z, Chen C, Cai S, et al. Low expression of MAP1LC3B, associated with low Beclin-1, predicts lymph node metastasis and poor prognosis of gastric cancer. Tumour Biol 2016;37:15007-17.
- Abstract Viewed: 142 times
- PDF Downloaded: 9 times